We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Glu9.0
Glucosamine Research
Likely helpsHigh safety
42 peer-reviewed studies
What the evidence says
Probably helps
Glucosamine helped in about half (9/13) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 2002–2026 with a typical study size of 164 participants.
Based on 42 studies · 18 meta-analyses · 11 RCTs · 521,554 total participants
Confidence
High
What the studies found
9helped1unclear3didn't help· 29 more without graded effect data
By outcome
Joint pain & arthritisReduced joint pain and improved mobility within 4-8 weeks · 4-8 weeks
Probably helps32 studies
Safety profile
Mostly mechanism / observational4 studies
InflammationMay reduce joint pain and slow cartilage loss · 4-12 weeks
Too few graded studies2 studies
Therapeutic & clinical
Too few graded studies2 studies
Heart & blood pressure
Too few graded studies1 study
Glucose & metabolic
Too few graded studies1 study
Longevity & aging
Too few graded studies1 study
By the numbers
Pulled from 29 studies with measurable effects
Likely real effects
67%
across studies
People studied
522k
typical study: 164 people
Strongest designs
29
18 pooled, 11 randomised
Showed benefit
69%
9/13 studies
How long studies ran
1–3 months
1
3+ months
9
Populations Studied
Patients with knee osteoarthritis5
Patients with osteoarthritis4
General population2
Knee osteoarthritis patients2
Active research area
21 studies in the last 5 years · Latest meta-analysis: 2025
200220142026
1Safety of anti-osteoarthritis medicationsSystematic ReviewCited 6×n=22,938 · very large study2025
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Honvo G et al. · Drugs (2025)
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Beyond the evidence here reported, the limitations of this research highlight the urgent need of a reporting guideline for post-marketing safety surveillance studies.
Importantly, real-life safety surveillance of anti-OA medications should be strengthened with large cohort studies with control groups, and results should be disaggregated by disease populations for drugs common to several conditions.
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
Meng Z et al. · Archives of orthopaedic and trauma surgery (2023)
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
It is worthwhile to popularize and apply the combination in KOA treatment considering the point of effect, tolerability and economic costs.
Additionally, regarding the limited number of studies and uneven trial quality, more high-quality trials are required to investigate the accurate clinical advantages of the combination.
3Knee osteoarthritis treatment effectivenessMeta-AnalysisCited 8×n=1,930 · large study2022
JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application.
Zhao J et al. · Journal of ethnopharmacology (2022)
Huge harm
← WorseNo effectBetter →
Likely real
The effective rate (OR = 2.56, 95% CI = 1.83 to 3.57, P < 0.001) and incidence of adverse reactions was significantly lower in the JWGT group than in the control group (OR = 0.13, 95% CI = 0.07 to 0.21, P < 0.001).
Compared with hyaluronic acid (HA) alone, JWGT + HA had better clinical efficacy (OR = 3.08, 95% CI = 1.48 to 6.40, P < 0.001).
JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application.
4PainMeta-AnalysisCited 20×n=2,952 · very large study2015
Well-planned, well-conducted and well-published trials are warranted to improve the evidence for Ayurvedic interventions.
Kessler CS et al. · Rheumatology international (2015)
Huge benefit
← WorseNo effectBetter →
Likely real
For the compound preparation, Rumalaya, large and apparently unbiased effects beyond placebo were found for pain (standardized mean difference [SMD] -3.73; 95 % confidence interval [CI] -4.97, -2.50; P < 0.01) and global improvement (risk ratio 12.20; 95 % CI 5.83, 25.54; P < 0.01).
There is also some evidence that effects of the herbal compound preparation Shunti-Guduchi are comparable to those of glucosamine for pain (SMD 0.08; 95 % CI -0.20, 0.36; P = 0.56) and function (SMD 0.15; 95 % CI -0.12, 0.36; P = 0.41).
No severe adverse events were observed in all trials.
5Efficacy for osteoarthritis and joint painSystematic ReviewCited 1×n=146 · medium study2025
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
Baden KER et al. · Nutrients (2025)
Huge benefit
← WorseNo effectBetter →
Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S.
Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects.
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
6Meta-AnalysisCited 38×n=16,427 · very large study2015
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
Zeng C et al. · Scientific reports (2015)
All treatment options showed clinically significant improvement from baseline pain, but only glucosamine plus chondroitin showed clinically significant improvement from baseline function.
In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing.
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
A review of randomized trials of mostly low quality reveals that chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with osteoarthritis in short-term studies.
Singh JA et al. · The Cochrane database of systematic reviews (2015)
Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low).
Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate).
Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug.
8Knee and hip osteoarthritis treatmentMeta-AnalysisCited 66×n=1,663 · large study2017
Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry.
Runhaar J et al. · Annals of the rheumatic diseases (2017)
Five trials (all independent of industry, n=1625) compared glucosamine with placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs.
Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry.
9Effectiveness and safety of SYSADOAs for knee osteoarthritisMeta-AnalysisCited 2×2025
Level of Evidence: Therapeutic Level II.
Park YB et al. · Medicina (Kaunas, Lithuania) (2025)
Regarding the safety profile, the risk ratios did not differ significantly between the treatment and control groups, including the placebo and non-placebo subgroups.
Conclusions: Glucosamine, chondroitin, and SKCPT/SKI306X improved the pain and function and were non-inferior to pharmacologic drugs for up to 12 months.
These findings support the clinical use of these SYSADOAs to treat knee OA.
10Cancer prevention with glucosamine and chondroitinMeta-AnalysisCited 2×2023
Moreover, NSAIDs use may have a synergistic protective effect.
Liu B et al. · Nutrition and cancer (2023)
Barely noticeable benefit
← WorseNo effectBetter →
The odds ratio (OR), corresponding to the 95% confidence interval (95% CI), was used to assess the association between chondroitin and/or glucosamine intake and cancer risk.
Overall, chondroitin and/or glucosamine intake was associated with a lower risk of colorectal cancer (OR = 0.91, 95% CI, 0.87-0.94) and lung cancer (OR = 0.84, 95% CI, 0.79-0.89).
Subgroup analysis supported the protective effect of different SYSADOAs (chondroitin and/or glucosamine) intake.
Further long-term, randomized, double-blind studies, with a unified methodology, ought to be performed to draw the general recommendations for the use of oral glucosamine in the treatment of TMJ OA.
Derwich M et al. · International journal of molecular sciences (2023)
Administration of oral glucosamine for a longer period of time, i.e., 3 months, led to a significant reduction in TMJ pain and a significant increase in maximum mouth opening.
The most important aspect affecting the clinical efficacy of oral glucosamine in the treatment of TMJ OA was the total administration time.
It also resulted in long-term anti-inflammatory effects within the TMJs.
13Joint space narrowingMeta-AnalysisCited 227×n=37 · small study2018
In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo.
Gregori D et al. · JAMA (2018)
Noticeable benefit
← WorseNo effectBetter →
Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, -0.42 [95% CrI, -0.65 to -0.19]), chondroitin sulfate (SMD, -0.20 [95% CrI, -0.31 to -0.07]), and strontium ranelate (SMD, -0.20 [95% CrI, -0.36 to -0.05]).
In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo.
Larger RCTs are needed to resolve the uncertainty around efficacy of medications for knee osteoarthritis.
14Pain and functionality in osteoarthritisMeta-AnalysisCited 6×n=35 · small study2017
We concluded it is not clear whether glucosamine decreases pain or improves functionality in osteoarthritis because the certainty of the evidence is very low.
Harrison-Muñoz S et al. · Medwave (2017)
To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple databases.
We identified 11 systematic reviews including 35 randomized trials answering the question of interest.
We extracted data, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.
The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low.
Liu X et al. · British journal of sports medicine (2018)
Another six (undenatured type II collagen, avocado soybean unsaponifiables, methylsulfonylmethane, diacerein, glucosamine and chondroitin) revealed statistically significant improvements on pain, but were of unclear clinical importance.
Chondroitin demonstrated statistically significant, but not clinically important structural improvement (effect size -0.30, -0.42 to -0.17).
The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low.
16Safety of symptomatic slow-acting drugs for osteoarthritisMeta-AnalysisCited 55×n=25 · very small study2019
GS and CS can be considered safe treatments for patients with OA.
Honvo G et al. · Drugs & aging (2019)
Huge harm
← WorseNo effectBetter →
In studies that allowed concomitant OA medications, diacerein was associated with significantly more dermatological disorders (OR 2.47; 95% CI 1.42-4.31; I2 = 0%) and more dropouts due to AEs (OR 3.18; 95% CI 1.85-5.47; I2 = 13.4%) than was placebo.
No significant increase in serious or severe AEs was found with diacerein versus placebo.
GS and CS can be considered safe treatments for patients with OA.
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.
Zhu X et al. · Journal of orthopaedic surgery and research (2018)
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.
Glucosamine showed effect on stiffness outcome.
Regarding on the limited number of combination therapy, further studies need to investigate the accurate effectiveness.
19Gastrointestinal complicationsSystematic ReviewCited 44×n=20 · very small study2018
Careful consideration should be given to medical management taking into account known co-morbidities.
Aweid O et al. · Journal of orthopaedic surgery (Hong Kong) (2018)
Huge harm
← WorseNo effectBetter →
Highest gastrointestinal complications were reported for diclofenac (odds ratio (OR) = 4.77 (3.94, 5.76)) and lowest for total knee replacement (HR = 0.6 (0.49, 0.75)).
Ibuprofen had the highest renal complications (OR = 2.32 (1.45, 3.71)), whereas celecoxib had the highest cardiovascular risk (OR = 2.26 (1, 5.1)) and lowest was for tramadol (RR = 1.1 (0.87, 1.4)).
Results show that medical management of hip and knee OA, particularly with non-steroidal anti-inflammatory drugs, may carry higher mortality compared to surgery.
Further studies are needed to evaluate the effect of glucosamine on knee function and joint preservation, as well as to evaluate the combined effect with other components, such as chondroitin.
Ogata T et al. · Clinical rheumatology (2018)
A newly established knee OA scale, the Japanese Knee Osteoarthritis Measure (JKOM), is commonly used in Japan.
Although the number of subjects was small, the JKOM meta-analysis indicated that glucosamine is superior to a placebo in alleviating knee OA symptoms.
Given this, we concluded that glucosamine has the potential to alleviate knee OA pain.